NO20034689D0 - Farmasöytiske doseringsformer av amorf nelfinavir mesylat - Google Patents
Farmasöytiske doseringsformer av amorf nelfinavir mesylatInfo
- Publication number
- NO20034689D0 NO20034689D0 NO20034689A NO20034689A NO20034689D0 NO 20034689 D0 NO20034689 D0 NO 20034689D0 NO 20034689 A NO20034689 A NO 20034689A NO 20034689 A NO20034689 A NO 20034689A NO 20034689 D0 NO20034689 D0 NO 20034689D0
- Authority
- NO
- Norway
- Prior art keywords
- dosage forms
- pharmaceutical dosage
- nelfinavir mesylate
- amorphous nelfinavir
- amorphous
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 229960005230 nelfinavir mesylate Drugs 0.000 title 1
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28841001P | 2001-05-03 | 2001-05-03 | |
| PCT/EP2002/004711 WO2002089835A2 (en) | 2001-05-03 | 2002-04-29 | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034689L NO20034689L (no) | 2003-10-20 |
| NO20034689D0 true NO20034689D0 (no) | 2003-10-20 |
Family
ID=23106974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034689A NO20034689D0 (no) | 2001-05-03 | 2003-10-20 | Farmasöytiske doseringsformer av amorf nelfinavir mesylat |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US7014866B2 (no) |
| EP (1) | EP1390063B1 (no) |
| JP (1) | JP4101661B2 (no) |
| KR (1) | KR100554816B1 (no) |
| CN (1) | CN1255185C (no) |
| AR (1) | AR034320A1 (no) |
| AT (1) | ATE282428T1 (no) |
| BG (1) | BG108311A (no) |
| BR (1) | BR0209325A (no) |
| CA (1) | CA2444116C (no) |
| CZ (1) | CZ20033211A3 (no) |
| DE (1) | DE60201988T2 (no) |
| EA (1) | EA006627B1 (no) |
| EC (1) | ECSP034827A (no) |
| ES (1) | ES2231717T3 (no) |
| GE (1) | GEP20053466B (no) |
| GT (1) | GT200200079A (no) |
| HK (1) | HK1070285A1 (no) |
| HR (1) | HRP20030873B1 (no) |
| HU (1) | HU229938B1 (no) |
| IL (2) | IL158306A0 (no) |
| IS (1) | IS7010A (no) |
| JO (1) | JO2401B1 (no) |
| MA (1) | MA27018A1 (no) |
| MX (1) | MXPA03009971A (no) |
| MY (1) | MY128509A (no) |
| NO (1) | NO20034689D0 (no) |
| NZ (1) | NZ528689A (no) |
| PA (1) | PA8544501A1 (no) |
| PE (1) | PE20021159A1 (no) |
| PL (1) | PL366998A1 (no) |
| PT (1) | PT1390063E (no) |
| RS (1) | RS83503A (no) |
| SK (1) | SK14572003A3 (no) |
| TW (1) | TWI234461B (no) |
| UA (1) | UA76463C2 (no) |
| WO (1) | WO2002089835A2 (no) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1175205B1 (en) | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| CA2398226A1 (en) * | 2002-01-28 | 2003-07-28 | Pfizer Inc. | Increased-dosage nelfinavir tablet and method of making same |
| JP4731320B2 (ja) | 2003-07-15 | 2011-07-20 | アリジェン製薬株式会社 | 抗コロナウイルス剤 |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| EP1701704A2 (en) * | 2003-12-31 | 2006-09-20 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
| BRPI0518781A2 (pt) * | 2004-12-03 | 2008-12-09 | Merck & Co Inc | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto |
| CN101267808A (zh) * | 2005-09-23 | 2008-09-17 | 弗·哈夫曼-拉罗切有限公司 | 新型制剂 |
| ES2350497T3 (es) * | 2005-12-14 | 2011-01-24 | F. Hoffmann-La Roche Ag | Formulación de profármacos para el vhc. |
| ATE482690T1 (de) * | 2005-12-14 | 2010-10-15 | Hoffmann La Roche | Hcv-prodrug-formulierung |
| TW200815033A (en) * | 2006-08-10 | 2008-04-01 | Cipla Ltd | Antiretroviral solid oral composition |
| CN101516339B (zh) | 2006-08-16 | 2012-06-13 | 诺瓦提斯公司 | 制备高度结晶的治疗化合物的固体分散体的方法 |
| CA2669938C (en) * | 2006-11-15 | 2016-01-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| EP2136637B1 (en) | 2007-03-16 | 2015-11-11 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
| BRPI0810362A2 (pt) * | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | Compostos de morfolinila deuterados |
| EP2152689B1 (en) | 2007-04-25 | 2013-01-02 | Concert Pharmaceuticals Inc. | Analogues of cilostazol |
| CA2630084A1 (en) * | 2007-04-30 | 2008-10-30 | Mark Andreychuk | Coiled tubing with retainer for conduit |
| US9194512B2 (en) | 2007-04-30 | 2015-11-24 | Mark Andreychuk | Coiled tubing with heat resistant conduit |
| EP2150525A1 (en) | 2007-05-01 | 2010-02-10 | Concert Pharmaceuticals Inc. | Naphthyl(ethyl) acetamides |
| AU2008247818B2 (en) | 2007-05-01 | 2011-10-20 | Sun Pharmaceutical Industries, Inc. | Morphinan compounds |
| EP4183787A1 (en) | 2007-05-01 | 2023-05-24 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| DK2792662T3 (da) | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| PL2003120T3 (pl) | 2007-06-12 | 2010-04-30 | Concert Pharmaceuticals Inc | Pochodne azapeptydu jako inhibitory proteazy HIV |
| EP2212298B1 (en) * | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20100222311A1 (en) * | 2007-10-19 | 2010-09-02 | Purdue Research Foundation | Solid formulations of crystalline compounds |
| ITMI20080227A1 (it) * | 2008-02-13 | 2009-08-14 | Felice Vinati | '' dispositivo di sicurezza per apparati di sollevamento a fune '' |
| JP5292413B2 (ja) | 2008-02-29 | 2013-09-18 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換キサンチン誘導体 |
| US20110160253A1 (en) * | 2008-05-28 | 2011-06-30 | Harbeson Scott L | Deuterated tizanidine |
| US20100221221A1 (en) * | 2008-08-12 | 2010-09-02 | Concert Pharmaceuticals Inc. | N-phenyl-2-pyrimidineamine derivatives |
| ES2656444T3 (es) | 2008-09-19 | 2018-02-27 | Concert Pharmaceuticals, Inc. | Compuestos de morfinano deuterados |
| US20120053169A1 (en) | 2008-10-30 | 2012-03-01 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| US20120083487A1 (en) | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| EP2362779A4 (en) | 2008-11-04 | 2013-03-20 | Anchor Therapeutics Inc | CXCR4 RECEPTOR COMPOUNDS |
| US20110313004A1 (en) | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| BRPI1009199A2 (pt) | 2009-03-17 | 2016-03-08 | Concert Pharmaceuticals Inc | compostos de pirazinoisoquinolina |
| US20120244122A1 (en) | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
| WO2011005520A1 (en) | 2009-06-23 | 2011-01-13 | Concert Pharmaceuticals, Inc. | Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| WO2011060216A1 (en) | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
| WO2011103457A1 (en) | 2010-02-18 | 2011-08-25 | Concert Pharmaceuticals Inc. | Pyrimidine derivatives |
| WO2011106703A2 (en) | 2010-02-26 | 2011-09-01 | Anchor Therapeutics, Inc. | Cxcr4 receptor compounds |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| EP2542534A1 (en) | 2010-03-02 | 2013-01-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
| US20130084335A1 (en) | 2010-06-14 | 2013-04-04 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition |
| WO2012037060A1 (en) | 2010-09-13 | 2012-03-22 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
| EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
| WO2012065028A2 (en) | 2010-11-11 | 2012-05-18 | Concert Pharmaceuticals Inc. | Substituted tetracyclines |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| US8447329B2 (en) | 2011-02-08 | 2013-05-21 | Longsand Limited | Method for spatially-accurate location of a device using audio-visual information |
| EP2678337A1 (en) | 2011-02-25 | 2014-01-01 | Concert Pharmaceuticals Inc. | 2-amino-naphthyridine derivatives |
| WO2012129381A1 (en) | 2011-03-22 | 2012-09-27 | Concert Pharmaceuticals Inc. | Deuterated preladenant |
| US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| US20140128469A1 (en) | 2011-05-10 | 2014-05-08 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
| WO2012158885A1 (en) | 2011-05-18 | 2012-11-22 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ivacaftor |
| WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| FR2985177B1 (fr) * | 2012-01-02 | 2016-04-01 | Oreal | Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs |
| US20150011466A1 (en) | 2012-01-09 | 2015-01-08 | Anchor Therapeutics, Inc. | APJ Receptor Compounds |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| AU2013245662A1 (en) | 2012-04-13 | 2014-10-30 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| WO2013159026A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| EP2861600A1 (en) | 2012-06-15 | 2015-04-22 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ruxolitinib |
| EP2885267B1 (en) | 2012-07-12 | 2018-09-05 | Concert Pharmaceuticals, Inc. | Deuterated idebenone |
| BR112015003153A2 (pt) | 2012-08-17 | 2017-07-04 | Concert Pharmaceuticals Inc | baricitinib deuterado |
| MY183582A (en) | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
| MX2015008187A (es) | 2012-12-20 | 2016-02-05 | Concert Pharmaceuticals Inc | Inhibidores de alk deuterados. |
| WO2014100733A1 (en) | 2012-12-21 | 2014-06-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014150043A1 (en) | 2013-03-15 | 2014-09-25 | Concert Pharmaceuticals Inc. | Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase |
| US20160024084A1 (en) | 2013-03-15 | 2016-01-28 | Concert Pharmaceuticals, Inc. | Deuterated palbociclib |
| HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
| WO2015009889A1 (en) | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
| US20160159861A1 (en) | 2013-07-18 | 2016-06-09 | Anchor Therapeutics, Inc. | APJ Receptor Compounds |
| US9676790B2 (en) | 2013-08-30 | 2017-06-13 | Concert Pharmaceuticals, Inc. | Substituted thienotriazolodiazapines |
| EP3105232B1 (en) | 2014-02-10 | 2019-08-28 | Concert Pharmaceuticals Inc. | Substituted triazolobenzodiazepines |
| CN106456647A (zh) | 2014-04-18 | 2017-02-22 | 康塞特医药品有限公司 | 治疗高血糖症的方法 |
| WO2015179772A1 (en) | 2014-05-23 | 2015-11-26 | Concert Pharmaceuticals, Inc. | Deuterated phenylquinazolinone and phenylisoquinolinone compounds |
| RU2705800C2 (ru) | 2014-06-06 | 2019-11-12 | Рисерч Трайэнгл Инститьют | Агонисты рецептора апелина (apj) и их применение |
| EP3808349B1 (en) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| WO2016061488A1 (en) | 2014-10-17 | 2016-04-21 | Concert Pharmaceuticals, Inc. | Amine reuptake inhibitors |
| WO2016073545A1 (en) | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
| WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
| US10301281B2 (en) | 2014-12-11 | 2019-05-28 | Merck Sharp & Dohme Corp. | Crystal forms of a CCR5 antagonist |
| CN105769809A (zh) * | 2014-12-23 | 2016-07-20 | 上海星泰医药科技有限公司 | 提高生物利用度的雷尼司他及其制备方法 |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| US20180044375A1 (en) | 2015-03-06 | 2018-02-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
| WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| CA2994169A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| WO2017020005A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Morphinan compounds for use in treating agitation |
| AU2016326441B2 (en) | 2015-09-21 | 2021-11-25 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated CFTR potentiators |
| EP3377179B1 (en) | 2015-11-19 | 2021-04-07 | Concert Pharmaceuticals Inc. | Deuterated epi-743 |
| MA43417A (fr) | 2015-12-09 | 2018-10-17 | Res Triangle Inst | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations |
| WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
| JP7145080B2 (ja) | 2016-05-04 | 2022-09-30 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化ｊａｋ阻害剤による脱毛障害の処置 |
| CN115215801A (zh) | 2016-07-04 | 2022-10-21 | 雅芳制药公司 | 氘代右美沙芬的合成方法 |
| US11596605B2 (en) | 2016-08-01 | 2023-03-07 | The Brigham And Women's Hospital, Inc. | Particles for delivery of proteins and peptides |
| US11596629B2 (en) | 2017-02-28 | 2023-03-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2018213609A1 (en) | 2017-05-17 | 2018-11-22 | Ausubel Frederick M | Antibiotic compounds |
| JP7228574B2 (ja) | 2017-05-19 | 2023-02-24 | スパーブ ウィズダム リミテッド | レシキモドの誘導体 |
| CA3082834A1 (en) | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| US20230390292A1 (en) | 2020-10-28 | 2023-12-07 | Sun Pharmaceutical Industries, Inc. | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
| WO2023018904A1 (en) | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| WO2023018954A1 (en) | 2021-08-12 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
| WO2023215520A1 (en) | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| US5834472A (en) | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6001851A (en) | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| JP4083818B2 (ja) * | 1997-06-06 | 2008-04-30 | ディポメド，インコーポレイティド | 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形 |
| AU8145198A (en) * | 1997-06-16 | 1999-01-04 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
| CA2302275C (en) * | 1997-09-19 | 2009-12-08 | Shire Laboratories, Inc. | Solid solution beadlet |
| MXPA02004739A (es) * | 1999-11-12 | 2003-01-28 | Abbott Lab | Formulaciones farmaceuticas de dispersion solida. |
| US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
-
2002
- 2002-04-29 WO PCT/EP2002/004711 patent/WO2002089835A2/en active IP Right Grant
- 2002-04-29 KR KR1020037014234A patent/KR100554816B1/ko not_active IP Right Cessation
- 2002-04-29 CA CA002444116A patent/CA2444116C/en not_active Expired - Fee Related
- 2002-04-29 HU HU0401238A patent/HU229938B1/hu not_active IP Right Cessation
- 2002-04-29 UA UA20031210981A patent/UA76463C2/uk unknown
- 2002-04-29 SK SK1457-2003A patent/SK14572003A3/sk unknown
- 2002-04-29 IL IL15830602A patent/IL158306A0/xx unknown
- 2002-04-29 PT PT02748680T patent/PT1390063E/pt unknown
- 2002-04-29 BR BR0209325-1A patent/BR0209325A/pt not_active Application Discontinuation
- 2002-04-29 AT AT02748680T patent/ATE282428T1/de active
- 2002-04-29 CN CNB028092953A patent/CN1255185C/zh not_active Expired - Fee Related
- 2002-04-29 CZ CZ20033211A patent/CZ20033211A3/cs unknown
- 2002-04-29 ES ES02748680T patent/ES2231717T3/es not_active Expired - Lifetime
- 2002-04-29 EA EA200301166A patent/EA006627B1/ru not_active IP Right Cessation
- 2002-04-29 DE DE60201988T patent/DE60201988T2/de not_active Expired - Lifetime
- 2002-04-29 MX MXPA03009971A patent/MXPA03009971A/es active IP Right Grant
- 2002-04-29 EP EP02748680A patent/EP1390063B1/en not_active Expired - Lifetime
- 2002-04-29 PL PL02366998A patent/PL366998A1/xx unknown
- 2002-04-29 JP JP2002586967A patent/JP4101661B2/ja not_active Expired - Fee Related
- 2002-04-29 RS YU83503A patent/RS83503A/sr unknown
- 2002-04-29 NZ NZ528689A patent/NZ528689A/en unknown
- 2002-04-29 GE GE5295A patent/GEP20053466B/en unknown
- 2002-04-30 PE PE2002000369A patent/PE20021159A1/es not_active Application Discontinuation
- 2002-04-30 AR ARP020101580A patent/AR034320A1/es not_active Application Discontinuation
- 2002-04-30 MY MYPI20021591A patent/MY128509A/en unknown
- 2002-04-30 PA PA20028544501A patent/PA8544501A1/es unknown
- 2002-04-30 TW TW091108967A patent/TWI234461B/zh not_active IP Right Cessation
- 2002-05-01 JO JO200237A patent/JO2401B1/en active
- 2002-05-02 GT GT200200079A patent/GT200200079A/es unknown
- 2002-05-02 US US10/138,071 patent/US7014866B2/en not_active Expired - Fee Related
-
2003
- 2003-10-08 IL IL158306A patent/IL158306A/en not_active IP Right Cessation
- 2003-10-20 NO NO20034689A patent/NO20034689D0/no not_active Application Discontinuation
- 2003-10-28 HR HR20030873A patent/HRP20030873B1/xx not_active IP Right Cessation
- 2003-10-30 IS IS7010A patent/IS7010A/is unknown
- 2003-10-31 EC EC2003004827A patent/ECSP034827A/es unknown
- 2003-11-03 MA MA27379A patent/MA27018A1/fr unknown
- 2003-11-03 BG BG108311A patent/BG108311A/bg unknown
-
2005
- 2005-04-11 HK HK05103024A patent/HK1070285A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034689D0 (no) | Farmasöytiske doseringsformer av amorf nelfinavir mesylat | |
| NO20030627D0 (no) | Hydrogel-drevet medikament doseringsform | |
| NO20033384L (no) | Farmasoytisk formulering | |
| ATE296619T1 (de) | Feste orale dosierungsform von simethicon | |
| NO20033343L (no) | Farmasöytiske doseringsformer av epothiloner for oral administrasjon | |
| ITTO20010008A0 (it) | Formulazione farmaceutica | |
| NO20033785L (no) | Farmasöytisk formulering | |
| NO20033556L (no) | Farmasöytiske formuleringer | |
| DE60308372D1 (de) | Dosierungsverabreichungsvorrichtung | |
| EE05020B1 (et) | Glburiidi ravimkoostis | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| NO20041607L (no) | Doseringsregime og farmasoytisk preparat for nodprevensjon | |
| DE60203537D1 (de) | 5ht1-rezeptoragonist enthaltendes arzneimittel | |
| NO20033162L (no) | Farmasöytisk tablett omfattende paroksetinmesylat | |
| DE60216899D1 (de) | Hormonsubstitutionstherapie und seine darreichungsformen | |
| DK1390063T3 (da) | Farmaceutisk doseringsform af amorft nelfinavir-mesylat | |
| TR200400375T3 (tr) | Taksanlarin sabit araliklarla dozlanmasi | |
| FI20012242A0 (fi) | Uudet farmaseuttiset yhdisteet | |
| FR2810862B1 (fr) | Ensemble de tables gigognes | |
| NO20041236L (no) | Farmasoytisk formulering | |
| UA5530S (uk) | Таблетка фармацевтична | |
| SE0102572D0 (sv) | Pharmaceutical formulation | |
| SE0101326D0 (sv) | Pharmaceutical formulation | |
| SE0101325D0 (sv) | Pharmaceutical formulation | |
| SE0102069D0 (sv) | Pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |